Why Is My Per-Case Margin Declining Even Though My Schedule Is Full?

Per-case margin declining in independent procedural facilities with full schedules almost always trace back to one source: commodity supply costs rising faster than anyone noticed, because the comparison that would have surfaced the gap was never run. The problem is structural, not clinical. It does not resolve when you add more cases. It compounds.

You have the volume. Cases are scheduled weeks out. The procedure mix has not changed. Staffing is stable. And yet the margin you are taking home on each case is lower than it was eighteen months ago — and you cannot point to a single obvious reason.

This is one of the most consistent patterns across independent ASCs, OBLs, and physician-owned practices. The cause is almost never what the P&L makes visible first.

What the Numbers Usually Show First

When per-case margin compresses in a facility with strong volume, the instinct is to look at staffing costs, payer mix shifts, or reimbursement changes. These are visible. They appear as named line items. They give you something to react to.

What does not appear as a named line item is commodity supply cost drift. It distributes itself across a dozen supply categories as small, incremental price increases — each one below the threshold that would trigger a review. A saline bag that cost $1.84 eighteen months ago costs $2.11 today. A contrast vial moved from $38 to $44. Custom pack pricing crept up on renewal. None of these individually looks like the source of a margin problem. Cumulatively, across every case you run in a month, they are.

The structural issue is that independent facilities — unlike hospital systems — do not have active procurement infrastructure monitoring SKU-level pricing against benchmarks. Distributor contracts auto-renew. Pricing adjusts within the terms of the agreement. Nobody inside the facility is comparing what you pay on a given SKU against what comparable independent facilities pay for that same item. That comparison has almost certainly never been done.

The Drift Pattern and How Long It Takes to Become Material

Commodity supply cost drift does not announce itself. It distributes across multiple supply categories as incremental increases that individually fall below any review threshold. The cumulative effect shows up as per-case margin compression that is easier to attribute to visible variables — staffing, payer mix, case complexity — than to supply pricing that has never been compared against a benchmark.

The compounding effect accelerates with volume. A facility running 80 cases per month and a facility running 160 cases per month may carry the same per-unit pricing gap on commodity supplies. The higher-volume facility accumulates that gap at twice the rate. A full schedule makes the revenue line stronger and the undetected cost variance more damaging simultaneously.

This is one of the most consistent patterns across independent ASCs, OBLs, and physician-owned practices. To illustrate how this math works: if commodity supply costs run $60 per case above what comparable independent facilities pay for the same SKUs, a facility running 120 cases per month accumulates $86,400 in annual overpayment on commodity supplies alone. That number is not hypothetical in direction — only in magnitude. Your facility’s actual figure requires your own purchase data compared against documented market rates. The direction of the gap is consistent. The size is what the benchmark reveals.

At a standard EBITDA multiple for independent procedural facilities — typically 4x to 6x for physician-owned ASCs and OBLs — a $60,000 to $90,000 annual commodity cost gap does not just represent recoverable cash. It represents $240,000 to $540,000 in suppressed enterprise value. That is the number most physician-owners have never been shown.

Why GPO Membership Does Not Solve This

Most independent facilities with a GPO relationship assume that membership is doing the work of cost management. It is not — at least not completely.

GPO pricing sets a contract floor. It does not guarantee that the facility is purchasing at the best available price within its category, and it does not include active monitoring of SKU-level pricing against benchmark facilities operating at comparable volume. The contract is only as valuable as the oversight applied to it. For most independent procedural facilities, that oversight does not exist. There is no dedicated procurement staff. There is no benchmark comparison. There is no mechanism to flag when pricing drifts above market without a formal review.

The per-case margin gap exists inside GPO relationships as readily as outside them. Volume tier misclassification alone — a facility operating at a volume that qualifies for a lower pricing tier but was never reclassified — accounts for a meaningful share of the per-unit variance documented across independent facilities. The contract says one thing. The invoice says another. Nobody checked.

The valuation article from Health Capital Consultants on OBL value drivers notes directly that GPOs “have not provided much benefit to OBLs in terms of pricing for endovascular devices” — and the commodity supply picture for independent facilities operating without active procurement management follows the same pattern.

What a Benchmark Actually Shows on Per-Case Margin Declining

A SKU-level commodity supply cost benchmark requires one input: 6 to 12 months of purchase history from your distributor. This is a standard usage and pricing export that any major distributor can provide to the account administrator on request. The export contains item-level pricing, order frequency, and purchase volume. That data is then compared against what comparable independent procedural facilities are paying for the same items, sourced from the same or equivalent distributors.

The benchmark surfaces three things: what you are currently paying on each key commodity SKU, what comparable facilities pay for the same item, and the annual dollar variance between those two numbers. That variance is your recoverable margin. It is not a projection. It is a comparison of actual pricing against documented market rates.

For independent ASCs and OBLs where this comparison has never been done, the gap is real and the direction is consistent. Whether it is $14,000 or $90,000 annually depends on your procedure mix, volume, and how long the pricing relationship has been running without a formal review.

The Question Behind the Question

If your per-case margin is declining and your volume is not the problem, the question is not where to cut. The question is where you are spending above market without knowing it.

For most independent facilities, that answer sits in commodity supply costs — and it has never been surfaced, because the benchmark data that makes the comparison possible is not something a facility can access on its own.

Knowing this pattern is one thing. Knowing your facility’s actual number against benchmark is another.

If you want to see where your facility stands, request your complimentary supply cost analysis at vantumpartners.com. We pull your purchase history, run the SKU-level comparison, and deliver the findings. You see your number. No strings, no pitch to join anything.

Frequently Asked Questions

Why does per-case margin decline even when revenue per case stays the same?

Revenue per case is only one side of the margin equation. If commodity supply costs — drugs, contrast, saline, procedure supplies, custom packs — increase incrementally over time without a corresponding review, cost per case rises while reimbursement stays flat. The margin compresses from the cost side, not the revenue side, and the mechanism is often invisible because no single line item increase is large enough to trigger a review on its own.

How do independent ASCs and OBLs compare to hospital systems on commodity supply costs?

Hospital outpatient departments typically purchase commodity supplies at lower effective prices than independent ASCs and OBLs operating at comparable clinical volume, because hospital systems have active procurement infrastructure, dedicated purchasing staff, and volume aggregation across multiple facilities. An independent OBL or ASC purchasing the same SKUs from the same distributor, without active contract oversight and without benchmark comparison, operates at a structural cost disadvantage that accumulates over time.

Does a GPO membership protect an independent facility from commodity cost drift?

GPO membership sets a contract pricing floor but does not actively monitor whether a facility is purchasing at the best available rate within its tier, nor does it flag when pricing drifts above market on renewal. For most independent procedural facilities, there is no mechanism inside the GPO relationship that would surface a per-unit pricing gap without a formal external benchmark comparison being run against actual purchase data. That benchmark — what comparable independent facilities are actually paying for the same SKUs — is not data the facility or its GPO can generate internally.

What data is needed to run a commodity supply cost benchmark for an ASC or OBL?

A commodity supply cost benchmark for an independent ASC or OBL requires 6 to 12 months of purchase history from the facility’s primary distributor. This is a standard usage and pricing report any major distributor or adminstrator can generate. The export contains SKU-level pricing, order quantities, and purchase frequency. That data is then compared against documented pricing for comparable independent facilities purchasing the same items.

How long does commodity supply cost drift typically take to become material in an independent facility?

Commodity supply cost drift typically becomes financially material over 18 to 36 months following a distributor contract establishment or auto-renewal without renegotiation. The rate at which it accumulates accelerates with case volume — a higher-volume facility compounds the per-unit variance faster than a lower-volume facility running the same gap. Most independent procedural facilities that have not run a formal benchmark comparison in the past two years are carrying some version of this gap.